KURA — structural market context
Structural market context from public regulatory and market data, shown with its as-of dates. Descriptive only: nothing on this page is a recommendation, a prediction, or advice to buy or sell any security.
What changed
As of the close on Nov 4. Each line shows the earlier value, the later value and their dates.
Change from the Nov 3 close to the Nov 4 close: −22.98%.
5.05× its 20-session average on Nov 4.
Includes pre- and post-market trading.
Short interest 14.3M shares (settlement Oct 15) vs 14.4M (Sep 30).
No new file loaded in this window. Latest file: settlement Oct 15, loaded Oct 27.
Latest file (settlements Oct 1–Oct 14, published Nov 3): 1 day with fails, largest 429 shares on Oct 8.
Previous file (settlements Sep 15–Sep 30, published Oct 16): 1 day with fails, largest 3K shares on Sep 17.
None recorded in this window.
None recorded in this window.
KURA events and their magnitude
KURA short interest & days to cover
FINRA consolidated short interest, reported twice a month and published ~2 weeks after each settlement date. % of float uses reported free float. · as of 2026-10-15 (21d ago)
KURA fails-to-deliver (FTD)
SEC fails-to-deliver files, published twice a month with ~6 weeks of delay.
KURA insider buying and selling (Form 4)
Last 12 months, Form 4 codes P and S: 2 purchases · 12 sales
SEC Form 4 filings: purchases and sales reported on Form 4 (transaction codes P and S) only; grants and option exercises excluded. Attributed public records.
KURA analyst ratings
Rating actions as published by the firms, from public feeds. They are not graded here.
Frequently asked questions
Other companies in the same SEC industry: Pharmaceutical Preparations
Industry: SIC code 2834 as recorded on SEC EDGAR.
KURA: the full history
Latest rows shown. Full history, market-wide screens, cluster detection and the context journal live in the dashboard.
Not financial advice. Trading involves risk. Descriptive structural context, never a recommendation.